Carlyle Signs Definitive Purchase Agreement to Acquire Colin Corp.

Tokyo, Japan – Global private equity firm The Carlyle Group today announced that it has signed definitive purchase agreements to purchase the assets of Colin Corp., a leading medical device manufacturer based in Komaki, Japan. The Colin brand name will continue to be utilized by the new entity. The transaction is expected to close by the end of December.

“Following the purchase, the restructured company will leverage Colin and Carlyle’s brand names and know-how to grow the business. Carlyle looks forward to working with Colin and its seasoned management team in strengthening the business. Colin’s leading technology in non-invasive blood pressure monitoring and its strong market position makes this a very attractive investment for Carlyle," said Tamotsu Adachi, Carlyle Managing Director.

Colin was established in 1975 initially as a blood pressure monitor manufacturer and has since broadened its product line to two primary lines of business. Colin’s Moneo business is a leader in the non-invasive blood pressure and patient monitoring market. Whereas, Colin’s AT business developed the epoch-making “VP1000/2000 device” (vascular profiling system), which screens for peripheral arterial disease utilizing a simpler process than that used by existing devices. The growth of the arteriosclerosis screening market has been rapid in recent years due to the increase in arteriosclerosis in Japan as well as the growing importance of preventive medicine. Carlyle highly regards the significance of Colin’s blood pressure products within Japan’s medical community as well as the future growth potential of Colin’s AT products and submitted a rehabilitation proposal, which was agreed upon by Colin. Carlyle was selected as sponsor after an auction process was conducted following Colin’s recent filing of Civil Rehabilitation Law, Minji Saisei Hou, or Chapter 11 equivalent in Japan.

# # #